Takashi Ogata

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Yuichiro� Doki, Jaffer A. Ajani, Ken Kato et al. · UCL Discovery (University College London) · 2022 · 532 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.

Ken Kato, Yoshinori Ito, Hiroyuki Daiko et al. · Journal of Clinical Oncology · 2022 · 193 citations

Medicine, Oncology, Radiation Oncology +17

Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer

Toru Aoyama, Taiichi Kawabe, Hirohito Fujikawa et al. · Annals of Surgical Oncology · 2014 · 146 citations

Medicine, Nutrition, Oncology +16

Impact of infectious complications on gastric cancer recurrence

Tsutomu Hayashi, Takaki Yoshikawa, Toru Aoyama et al. · Gastric Cancer · 2014 · 121 citations · Full text

Medicine, Oncology, Surgery +14

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.

Ian Chau, Yuichiro� Doki, Jaffer A. Ajani et al. · Journal of Clinical Oncology · 2021 · 111 citations

Medicine, Oncology, Pharmacology +17